"Health wise I am feeling great. I am a big supporter of trials - it allows new treatments and drugs to be brought in.”
A trial of ONY-P1 vaccine for prostate cancer that is not responding to hormone therapy
This trial was looking at a vaccine for prostate cancer that is not responding to hormone therapy (hormone refractory prostate cancer).
Researchers are looking for new prostate cancer treatments that will help men who are no longer responding to hormone therapy. This trial was very early research into vaccine treatment. The aims of the trial were to
- Find out more about how the immune system responds to the vaccine
- See how the vaccine affects the PSA level in the blood
- Learn more about the side effects
Summary of results
The trial team learnt more about how the immune system responds to the vaccine. They also found that in some men, the vaccine slowed down the speed at which their PSA level was rising. (In other words, it carried on going up, but more slowly than it had been).
- The trial recruited 26 men who had been having hormone therapy for prostate cancer, but had a rising PSA
- In 11 men, the rate of rise in PSA slowed down
- About half the men had a reaction at the injection site, but there were no serious side effects
The researchers published these results in 2005. At that time, they compared their results with recent studies of other experimental treatments for men with prostate cancer no longer responding to hormone therapy. They found that on average, it took longer for the cancer to start growing again in men who had the vaccine than in men who had other types of treatment.
We have based this summary on information from the team who ran the trial. The information they sent us has been reviewed by independent specialists (
How to join a clinical trial
Dr Hardev Pandha